Radiotherapy sentiment in @NYTimes is eye-opening. Since 2009, over half of articles show negative bias towards RT, while only 1/4 are positive. Despite major advancements in tech like MR-Linac, adaptive RT, & heavy ions, media celebration is scarce.
thegreenjournal.com/article/S0167-…
1/7

💯 Le 21 et 22 Mars à #Bordeaux , j'aurai l 'honneur de présider le 5ème congrès du GFRU.

🇫🇷 Nous serons ravis de vous accueillir nombreux pour aborder les sujets du programme ci joint.

📧 Lien d' inscription ici : espacecanalevenements.com/inscription-ev…

Re-irradiation requires dedicated planning solutions. We’ve previously reported on EQD2-based reRT planning accounting for previous dose. With collaborators at RaySearch, we've now published the underlying optimisation algorithms
doi.org/10.1002/mp.168… #medphys #radonc

We summarized the prospective evidence on efficacy and safety of MDT in mPCa. Marcin Miszczyk Shahrokh F. Shariat Ploussard Guillaume europeanurology.com/article/S0302-…

Takafumi Yanagisawa Zuzanna Nowicka Ekaterina Laukhtina Tatsushi Kawada Markus von Deimling Benjamin Pradere Juan Gómez Rivas Giorgio Gandaglia Supiot Stéphane Thomas Zilli Quoc-Dien Trinh, MD, MBA Alberto Briganti Piet Ost

Nicholas van As late breaking abstract of PACE B; conventional #radiotherapy versus SABR for #prostatecancer . Non-inferiority primary endpoint for bPFS met. 1.44% difference in 5-yr bPFS b/w arms (~95%) each. No difference in GI tox, GU 2 tox ⬆️ with SABR up to 6-9mo later #radonc #pcsm

🧵1/ 🙏🏾🙏🏾Thank you patients, families, trial staff and investigators for participating in TROG Cancer Research
15.03 FASTRACK II! This trial recruited n=70 across 8 sites in 🇦🇺 and 🇳🇱 #ASTRO23 ! #radonc #kcsm #radiotherapy ANZUP Kidney Cancer

🧵2/ SABR is a novel treatment for primary #kidneycancer which is non-invasive and has fewer technical limitations than thermal ablation. We tested SABR in a 🦘&🌷phase II trial for primary RCC that was inoperable or high-risk for surgery. The benchmark was 90% control at 1-year.

🧵3/ Eligible patients had an MDM recommendation for active treatment, 100% biopsy confirmed, eGFR>30. ~1/3 had T1a disease, most had larger (median size 46mm, largest 89mm). RENAL complexity ~8. n=70, patient follow-up as below ⬇️ Grant Stewart #ASTRO23 #radonc IKCC Kidney Cancer

🧵4/ Median F/U=43months. 100% local control + cancer specific survival throughout the lifetime of the trial – i.e. no patient failed or died of cancer. Renal function decline similar to partial nephrectomy; baseline eGFR=60mls/min, ⬇️14.6mls/min post SABR. #ASTRO23 Kidney Cancer

🧵5/ Tumour size ⬆️⬆️ than RCTs of PN v RN. Toxicity acceptable. As yet, there are no published clinical trials of thermal ablation; therefore, SABR is now a acceptable standard of care for inoperable RCC. FASTRACK II findings should lead to an RCT vs surgery. #ASTRO23 #radonc

🇫🇷GFRU guidelines for the management of biochemical relapse after RP
💙In press, Cancer Treatment Reviews💚
Thomas Zilli
Supiot Stéphane
GFRU
carl salembier
Mario Terlizzi
Talar Derashodian
CRÉHANGE Gilles

sciencedirect.com/science/articl…

Bradley Stish Matthew Ward Where are the data to add ARSI in a pelvic LN relapse seen on a PET?
This is not a Stampede like cN+disease but a biochemical relapse...
Piet Ost

I would include this patient in Carlha-2 or treat him following Oligopelvis (6 months ADT + elective EBRT)
Supiot Stéphane

🟡 DARIUS phase II randomized trial 🟡
GETUG
Association Française d'Urologie - AFU

➡️➡️ Darolutamide vs ADT
In combination with RT for intermediate risk PCa

🙏Congrats to all investigators for the 15 pts included (N=62)
Supiot Stéphane Ulrike Schick Jonathan Khalifa David Pasquier Jonathan Khalifa

Salvage SABR for intraprostatic tumour recurrences after external beam radiotherapy for prostate cancer. Read the phase 1 results from the GETUG-AFU 31 multicentre study

buff.ly/47kzAzW

David Pasquier Supiot Stéphane Genevieve LOOS Luc Cormier

#prostatecancer

🌟 The GFRU proposed
an easily-applicable, reproducible, and practice-validated guideline for the delineation of the pelvic CTV in PCa.
☀️ Best Team ever : Thomas Zilli Vérane Achard carl salembier Roubaud Guilhem
GFRU Supiot Stéphane
Guillaume Le Bihan...
redjournal.org/article/S0360-…

Published in SNO #Spectroscopy guided multicentric phase 3 trial of #radiotherapy dose-painting for newly diagnosed #glioblastoma
👉180 patients
👉72 Gy boost vs. 60Gy.
👉No added toxicity no OS /EFS improvement .
👉but 38 months OS with 72Gy if MGMT+
👉prospective QC

The role of radiation therapy for de novo metastatic #BladderCancer and #Kidneycancer .
🇫🇷 A Review on behalf of the SFRO.
Thanks a lot
Jonathan Khalifa David Pasquier Supiot Stéphane Azria David
Laurence Albiges Roubaud Guilhem
Pierre Blanchard, MD
⬇️⬇️⬇️
sciencedirect.com/science/articl…

Abs#5063 #ASCO23 ASCO: Interesting data showing lack of PSMA upregulation on early PSMA PET up to 30 days after initiation of AR pathway inhibitors for advanced #prostatecancer

➡️ any implications for combination ARPI + Lu-PSMA studies?

ICECAP: PSAnadir ≥0.1ng/mL within 6 months after RT completion is a strong prognostic marker for:

🔘PCa-specific survival (PCSS)
🔘Metastasis-free survival (MFS)
🔘Overall survival (OS) in patients receiving RT+ADT for localized #prostatecancer
Praful Ravi silke gillessen…